Cigna claimed that by imposing a cost cap, “financial predictability” would be provided, enabling companies and health plans to more effectively plan for managing GLP-1 spending. Thus, more access for qualified patients would be ensured.
During the company’s investor day, Express Scripts’ head of pharmacy benefits management, Adam Kautzner, predicted that the GLP-1 market might reach $100 billion by the end of the decade. The Evernorth division is the owner of ExpressScripts. He described that as a “totally unsustainable number” and stated that customers of Cigna’s insurance division are “still coming to us for assistance.”